About this ETF
The investment seeks results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Global Longevity Thematic Index. The fund invests more than 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that facilitate the demographic trend of longer average life spans and the aging of the global population, including but not limited to companies involved in biotechnology, medical devices, pharmaceuticals, senior living facilities and specialized health care services.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -0.08% | +5.10% | +9.64% | +7.70% | +10.02% | +6.29% | +7.01% | — | +9.00% |
| Total return | -0.07% | +5.10% | +9.64% | +7.71% | +10.02% | +6.69% | +7.54% | — | +9.55% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through May 22, 2023. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.50% | Annual cost of a $10,000 investment | $50.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Apr 17, 2023 — portfolio reporting date from the data provider; holdings are not live positions. 99 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ELI LILLY & CO | LLY | 4.04% | 4.57K | $1.7M |
| 2 | AMGEN INC | AMGN | 3.84% | 5.59K | $1.6M |
| 3 | BRISTOL-MYERS SQUIBB CO | BMY | 3.56% | 18.55K | $1.5M |
| 4 | REGENERON PHARMACEUTICALS | REGN | 3.52% | 1.97K | $1.5M |
| 5 | NOVO NORDISK A/S-B | — | 3.48% | 12.08K | $1.4M |
| 6 | BOSTON SCIENTIFIC CORP | BSX | 3.35% | 31.36K | $1.4M |
| 7 | JOHNSON & JOHNSON | JNJ | 3.29% | 7.67K | $1.4M |
| 8 | BIOGEN INC | BIIB | 3.25% | 4.39K | $1.3M |
| 9 | ASTRAZENECA PLC-SPONS ADR | AZN | 3.24% | 20.24K | $1.3M |
| 10 | ABBVIE INC | ABBV | 3.20% | 8.28K | $1.3M |
| 11 | DEXCOM INC | DXCM | 2.98% | 10.97K | $1.2M |
| 12 | STRYKER CORP | SYK | 2.94% | 5.21K | $1.2M |
| 13 | ALCON INC | ALC.SW | 2.91% | 17.69K | $1.2M |
| 14 | ROCHE HOLDING AG-BR | RO.SW | 2.89% | 3.04K | $1.2M |
| 15 | CHUGAI PHARMA CO | 4519.T | 2.69% | 42.52K | $1.1M |
| 16 | WELLTOWER INC | WELL | 2.43% | 14.41K | $1.0M |
| 17 | MEDTRONIC PLC | MDT | 2.40% | 12.52K | $990.2K |
| 18 | EDWARDS LIFESCIENCES CORP | EW | 2.15% | 11.62K | $887.2K |
| 19 | GENMAB A/S | — | 2.11% | 1.97K | $872.1K |
| 20 | ASTELLAS PHARMA INC | 4503.T | 2.05% | 54.86K | $845.1K |
| 21 | ZIMMER BIOMET HO | ZBH | 1.81% | 6.26K | $746.5K |
| 22 | SEAGEN INC | SGEN | 1.64% | 5.47K | $675.2K |
| 23 | TERUMO CORP | 4543.T | 1.59% | 22.71K | $657.7K |
| 24 | INSULET CORP | PODD | 1.47% | 2.07K | $608.3K |
| 25 | STRAUMANN HOLDING AG-REG | STMN.SW | 1.36% | 4.76K | $562.8K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.18% | Paid (last 12 months) | $0.3277 |
| Frequency | Semi-Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 29, 2026 | Last payment | $0.1555 |
| Growth 1Y | +13.66% | Growth 3Y / 5Y (ann.) | +29.30% / +29.77% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 29, 2026 | — | — | $0.1555 |
| Dec 30, 2025 | — | — | $0.1722 |
| Jun 27, 2025 | — | — | $0.1422 |
| Dec 30, 2024 | — | — | $0.1462 |
| Dec 28, 2023 | — | — | $0.1213 |
| Jun 29, 2023 | — | — | $0.1516 |
| Dec 30, 2021 | — | — | $0.1743 |
| Jun 29, 2021 | — | — | $0.0340 |
| Dec 30, 2020 | Dec 31, 2020 | Jan 08, 2021 | $0.0550 |
| Jun 29, 2020 | Jun 30, 2020 | Jul 08, 2020 | $0.0450 |
| Dec 30, 2019 | Dec 31, 2019 | Jan 08, 2020 | $0.0899 |
| Jun 27, 2019 | Jun 28, 2019 | Jul 08, 2019 | $0.0530 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 2.81K | Average volume | 13.67K |
| AUM | $40.1M | Premium/Discount | -1.84% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for LNGR
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
LNGR